| Name | Baicalein |
| Description | Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor. |
| Cell Research | MTT assay is conducted to evaluate the effect of baicalein on proliferation of breast cancer cells. MDA-MB-231 cells are routinely digested, collected, and then seeded in 96-well plates at a density of 8×103 cells/well. After incubation for 12-24 hours, cells are treated with 0, 20, 40, 60, 80, 100, and 120 μM baicalein according to their experimental grouping and then incubated at 37°C for 24, 48, and 72 hours[3]. |
| In vitro | Baicalein effectively inhibits T cell proliferation and cytokine secretion in response to mitogens in vitro. It has been observed that pre-treatment with baicalein markedly reduces both Con A or anti-CD3/CD28 mAb-induced cell proliferation and cytokine release at a concentration of 25 μM. Additionally, baicalein initiates NF-κB DNA binding while concurrently inhibiting nuclear thioredoxin activity. Furthermore, baicalein hampers the proliferation, migration, and invasion of MDA-MB-231 cells in both a time- and dose-dependent manner, significantly lowering SATB1 expression in these cells. It also diminishes the expression of Wnt1 and β-catenin proteins, along with the transcription of Wnt/β-catenin-regulated genes. |
| In vivo | Baicalein effectively reduces graft versus host disease induction without hindering T-cell homeostatic proliferation in mice, demonstrating its significant anti-inflammatory properties in vivo[2]. Further, in rats, baicalein administration guards against elevated heart to body weight ratios, increases in plasma brain natriuretic peptide levels, intraventricular septum thickness, and myocardial collagen volume in the left ventricle (all P<0.05, respectively). Its antifibrotic action is underscored by the reduced expression of pro-collagens I and III in the left ventricle, alongside diminished expression of 12-lipoxygenase, and lowered expression and activity of matrix metallopeptidase 9 and extracellular signal-regulated kinases, thus demonstrating baicalein's capability to inhibit cardiac fibrosis in hypertensive rats[4]. |
| Storage | store under nitrogen,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 70.7 mg/mL (261.62 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1.35 mg/mL (5 mM), Solution.
|
| Keywords | XO | XanthineOxidase | Xanthine Oxidase | Inhibitor | inhibit | InfluenzaVirus | Influenza Virus | Ferroptosis | Baicalein |
| Inhibitors Related | Ethoxyquin | Kaolin | Allopurinol | Hemin | L-Glutamic acid | Ethyl linoleate | Magnesium acetate tetrahydrate | L-Cystine | L-Ascorbic acid sodium salt | Dimethyl phthalate | Sodium Molybdate | β-Cyclodextrin |
| Related Compound Libraries | Polyphenolic Natural Product Library | Flavonoid Natural Product Library | Traditional Chinese Medicine Monomer Library | Miao medicine Compound Library | Anti-Viral Compound Library | Anti-Inflammatory Traditional Chinese Medicine Compound Library | Immunology/Inflammation Compound Library | Anti-infective Natural Product Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Ancient Chinese Classical Formulas Compound Library | Anti-Cancer Active Compound Library |
United States
